Strategies to target tumors using nanodelivery systems based on biodegradable polymers, aspects of intellectual property, and market

Journal of Chemical Biology

Volumn 6, Issue 1, 2013, Pages 7-23

  Oliveira, Michele F ^a   Guimarães, Pedro P G ^a   Gomes, Alinne D M ^a   Suárez, Diego ^a   Sinisterra, Rubén D ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Biodegradable polymers; Cancer; Intellectual property; Nanodelivery systems; Targeting

Indexed keywords

3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; 4 [1 (3 FLUOROBENZYL) 5 INDAZOLYLAMINO] 5 METHYLPYRROLO[2,1 F][1,2,4]TRIAZINE 6 CARBAMIC ACID 3 MORPHOLINOMETHYL ESTER; AFATINIB; ALIPHATIC COMPOUND; AXD 2171; BEVACIZUMAB; BMS 690514; CEDIRANIB; CISPLATIN; DACOMITINIB; ERLOTINIB; LAPATINIB; LINIFANIB; MOTESANIB; NANOCARRIER; PACLITAXEL; PAZOPANIB; POLYESTER; POLYGLACTIN; POLYMER; PTK 87; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VARLITINIB; VATALANIB; WHEAT GERM AGGLUTININ; XL 647;

CHEMICAL STRUCTURE; DRUG DELIVERY SYSTEM; DRUG MARKETING; DRUG NANODELIVERY SYSTEM; HUMAN; MOLECULARLY TARGETED THERAPY; NANOTECHNOLOGY; NONHUMAN; PATENT; PRIORITY JOURNAL; REVIEW; SOLID TUMOR;

EID: 84872293055     PISSN: 18646158     EISSN: 18646166     Source Type: Journal    
DOI: 10.1007/s12154-012-0086-x     Document Type: Review

References (155)

1. Hamdy S, Haddadi A, Hung RW, Lavasanifar A (2011) Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv Drug Deliv Rev 63(10-11):943-955
2. Shen H, You J, Zhang G, Ziemys A, Li Q, Bai L, Deng X, Erm DR, Liu X, Li C, Ferrari M (2012) Cooperative, nanoparticle-enabled thermal therapy of breast cancer. Adv Healthc Mater 1(1):84-89. doi: 10.1002/adhm.201100005
3. WHO (2008) http://www.who.int. Accessed 21 March 2012
4. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2(3):161-174
5. Ferguson TA, Choi J, Green DR (2011) Armed response: how dying cells influence T-cell functions. Immunol Rev 241:77-88
6. Veiseh O, Kievit FM, Ellenbogen RG, Zhang M (2011) Cancer cell invasion: treatment and monitoring opportunities in nanomedicine. Adv Drug Deliv Rev 63(8):582-596
7. Barton CL (2011) Innovations in the delivery of cancer therapies. Business Insights
8. Chabner BA, Roberts TG (2005) Timeline - chemotherapy and the war on cancer. Nat Rev Cancer 5(1):65-72. doi: 10.1038/nrc1529
9. Lewis LD (2006) Cancer pharmacotherapy: 21st century 'magic bullets' and changing paradigms. Br J Clin Pharmacol 62(1):1-4. doi: 10.1111/j.1365-2125. 2006.02721.x
10. Teixeira LA, Fonseca CO (2007) De doença desconhecida a problema de saúde pública: o INCA e o controle do câncer no Brasil. http://www.inca.gov.br Acessed 28 Aug 2012
11. ACS (2012) http://www.acs.org. Accessed 10 Jan 2012
12. Rosenberg B, Camp L, Grimley E, Thomson A (1967) The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum (IV) complexes. J Biol Chem 242(25):1347-1352
13. Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4(4):307-320. doi: 10.1038/nrd1691
14. Zhang CX, Lippard SJ (2003) New metal complexes as potential therapeutics. Curr Opin Chem Biol 7(4):481-489
15. Ferrari M (2005) Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5(3):161-171. doi: 10.1038/nrc1566
16. Guo J, Bourre L, Soden DM, O'Sullivan GC, O'Driscoll C (2011) Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics? Biotechnol Adv 29(4):402-417
17. Haile S (2008) Cancer metastasis and in vivo dissemination of tissue-dwelling pathogens: extrapolation of mechanisms and exchange of treatment strategies thereof. Med Hypotheses 70(2):375-377
18. Rowinsky E, Donehower R (1995) Paclitaxel (Taxol). N Engl J Med 332(15):1004-1014
19. Soppimath KS, Liu LH, Seow WY, Liu SQ, Powell R, Chan P, Yang YY (2007) Multifunctional core/shell nanoparticles self-assembled from pH-induced thermosensitive polymers for targeted intracellular anticancer drug delivery. Adv Funct Mater 17(3):355-362. doi: 10.1002/adfm.200500611
20. Wang H, Zhao Y, Wu Y, Hu YL, Nan KH, Nie GJ, Chen H (2011) Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials 32(32):8281-8290. doi: 10.1016/j.biomaterials.2011.07.032
21. Takahara PM, Rosenzweig AC, Frederick CA, Lippard SJ (1995) Crystal-structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature 377(6550):649-652. doi: 10.1038/377649a0
22. Oerlemans C, Bult W, Bos M, Storm G, Nijsen JFW, Hennink WE (2010) Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm Res 27(12):2569-2589. doi: 10.1007/s11095-010-0233-4
23. Dinarvand R, Sepehri N, Manoochehri S, Rouhani H, Atyabi F (2011) Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents. Int J Nanomed 6:877-895. doi: 10.2147/ijn.s18905
24. Vergaro V, Scarlino F, Bellomo C, Rinaldi R, Vergara D, Maffia M, Baldassarre F, Giannelli G, Zhang X, Lvov YM, Leporatti S (2011) Drug-loaded polyelectrolyte microcapsules for sustained targeting of cancer cells. Adv Drug Deliv Rev 63(9):847-864
25. Peer D, Karp JM, Hong S, FaroKhzad OC, Margalit R, Langer R (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2(12):751-760. doi: 10.1038/nnano.2007.387
26. Alexandrakis G, Brown EB, Tong RT, McKee TD, Campbell RB, Boucher Y, Jain RK (2004) Two-photon fluorescence correlation microscopy reveals the two-phase nature of transport in tumors. Nat Med 10(2):203-207. doi: 10.1038/nm981
27. Geng Y, Dalhaimer P, Cai SS, Tsai R, Tewari M, Minko T, Discher DE (2007) Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol 2(4):249-255. doi: 10.1038/nnano.2007.70
28. Ramanujan S, Pluen A, McKee TD, Brown EB, Boucher Y, Jain RK (2002) Diffusion and convection in collagen gels: Implications for transport in the tumor interstitium. Biophys J 83(3):1650-1660
29. Acharya S, Sahoo SK (2011) PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev 63(3):170-183. doi: 10.1016/j.addr.2010.10.008
30. Alexis F, Rhee J-W, Richie JP, Radovic-Moreno AF, Langer R, Farokhzad OC (2008) New frontiers in nanotechnology for cancer treatment. Urol Oncol-Semin Ori Inv 26(1):74-85
31. Bangham AD, Standish MM, Watkins JC (1965) Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 13(1):238, IN227
32. Duncan R (2006) Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 6(9):688-701
33. Haley B, Frenkel E (2008) Nanoparticles for drug delivery in cancer treatment. Urol Oncol-Semin Ori Inv 26(1):57-64. doi: 10.1016/j.urolonc.2007.03. 015
34. Thei DP, Eric Drexler JK et al (2006) Nanotechnology. Nat Nano 1(1):8-10
35. Wang M, Thanou M (2010) Targeting nanoparticles to cancer. Pharmacol Res 62(2):90-99
36. Sahoo SK, Parveen S, Panda JJ (2007) The present and future of nanotechnology in human health care. Nanomed-Nanotechnol Biol Med 3(1):20-31. doi: 10.1016/j.nano.2006.11.008
37. Brannon-Peppas L, Blanchette JO (2004) Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 56(11):1649-1659
38. Davis ME, Chen Z, Shin DM (2008) Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7(9):771-782
39. Jain RK, Stylianopoulos T (2010) Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 7(11):653-664. doi: 10.1038/nrclinonc.2010.139
40. Zhuo C (2010) Small-molecule delivery by nanoparticles for anticancer therapy. Trends Mol Med 16(12):594-602
41. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65(1-2):271-284. doi: 10.1016/s0168-3659(99)00248-5
42. Kloover JS, den Bakker MA, Gelderblom H, van Meerbeeck JP (2004) Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer 90(2):304-305. doi: 10.1038/sj.bjc.6601301
43. Farokhzad OC, Langer R (2009) Impact of nanotechnology on drug delivery. Acs Nano 3(1):16-20. doi: 10.1021/nn900002m
44. Ghosh K, Kanapathipillai M, Korin N, McCarthy JR, Ingber DE (2012) Polymeric nanomaterials for islet targeting and immunotherapeutic delivery. Nano Lett 12:203-208. doi: 10.1021/nl203334c
45. Parveen S, Misra R, Sahoo SK (2012) Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine 8:147-166
46. Prakash S, Malhotra M, Shao W, Tomaro-Duchesneau C, Abbasi S (2011) Polymeric nanohybrids and functionalized carbon nanotubes as drug delivery carriers for cancer therapy. Adv Drug Deliv Rev 63(14-15):1340-1351
47. Janakiram NB, Rao CV (2008) Molecular markers and targets for colorectal cancer prevention. Acta Pharmacol Sin 29(1):1-20. doi: 10.1111/j.1745-7254.2008. 00742.x
48. Mahmud A, Xiong XB, Aliabadi HM, Lavasanifar A (2007) Polymeric micelles for drug targeting. J Drug Target 15(9):553-584. doi: 10.1080/10611860701538586
49. Ma WW, Adjei AA (2009) Novel agents on the horizon for cancer therapy. CA Cancer J Clin 59(2):111-137. doi: 10.3322/caac.20003
50. Dhanikula AB, Panchagnula R (1999) Localized paclitaxel delivery. Int J Pharm 183(2):85-100. doi: 10.1016/s0378-5173(99)00087-3
51. Bissell MJ, Radisky D (2001) Putting tumours in context. Nat Rev Cancer 1(1):46-54. doi: 10.1038/35094059
52. Byrne JD, Betancourt T, Brannon-Peppas L (2008) Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 60(15):1615-1626
53. Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8(8):579-591. doi: 10.1038/nrc2403
54. Francavilla C, Maddaluno L, Cavallaro U (2009) The functional role of cell adhesion molecules in tumor angiogenesis. Semin Cancer Biol 19(5):298-309. doi: 10.1016/j.semcancer.2009.05.004
55. Hynes RO (2002) A reevaluation of integrins as regulators of angiogenesis. Nat Med 8(9):918-921. doi: 10.1038/nm0902-918
56. Kobayashi H, Boelte KC, Lin PC (2007) Endothelial cell adhesion molecules and cancer progression. Curr Med Chem 14(4):377-386. doi: 10.2174/ 092986707779941032
57. Li LY, Wartchow CA, Danthi SN, Shen ZM, Dechene N, Pease J, Choi HS, Doede T, Chu P, Ning SC, Lee DY, Bednarski MD, Knox SJ (2004) A novel antiangiogenesis therapy using an integrin antagonist or anti-FLK-1 antibody coated Y-90-labeled nanoparticles. Int J Radiat Oncol Biol Phys 58(4):1215-1227. doi: 10.1016/j.ijrob.2003.10.057
58. Zhao YS, Bachelier R, Treilleux I, Pujuguet P, Peyruchaud O, Baron R, Clement-Lacroix P, Clezardin P (2007) Tumor alpha(nu)beta(3) integrin is a therapeutic target for breast cancer bone metastases. Cancer Res 67(12):5821-5830. doi: 10.1158/0008-5472.can-06-4499
59. Guarneri V, Dieci MV, Conte P (2012) Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. Expert Opin Pharmacother 13(3):395-406. doi: 10.1517/14656566.2012.651127
60. Kim JG (2007) Cancer nanotechnology: engineering multifunctional nanostructures for targeting tumor cells and vasculatures. Georgia Institute of Technology, Atlanta
61. Daniels TR, Delgado T, Helguera G, Penichet ML (2006) The transferrin receptor. Part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol 121(2):159-176. doi: 10.1016/j.clim.2006.06.006
62. Low PS, Antony AC (2004) Folate receptor-targeted drugs for cancer and inflammatory diseases - preface. Adv Drug Deliv Rev 56(8):1055-1058. doi: 10.1016/j.addr.2004.02.003
63. Lu YJ, Low PS (2002) Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol Immunother 51(3):153-162. doi: 10.1007/s00262-002-0266-6
64. Richardson DR, Kalinowski DS, Lau S, Jansson PJ, Lovejoy DB (2009) Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochim Biophys Acta, Gen Subj 1790(7):702-717. doi: 10.1016/j.bbagen.2008.04.003
65. Sridhar SS, Seymour L, Shepherd FA (2003) Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 4(7):397-406. doi: 10.1016/s1470-2045(03)01137-9
66. Jabr-Milane LS, van Vlerken LE, Yadav S, Amiji MM (2008) Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev 34(7):592-602. doi: 10.1016/j.ctrv.2008.04.003
67. Kateb B, Chiu K, Black KL, Yamamoto V, Khalsa B, Ljubimova JY, Ding H, Patil R, Portilla-Arias JA, Modo M, Moore DF, Farahani K, Okun MS, Prakash N, Neman J, Ahdoot D, Grundfest W, Nikzad S, Heiss JD (2011) Nanoplatforms for constructing new approaches to cancer treatment, imaging, and drug delivery: what should be the policy? NeuroImage 54(1):S106-S124
68. Shapira A, Livney YD, Broxterman HJ, Assaraf YG (2011) Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Updat 14(3):150-163
69. Singh R, Lillard JW (2009) Nanoparticle-based targeted drug delivery. Exp Mol Pathol 86(3):215-223. doi: 10.1016/j.yexmp.2008.12.004
70. Gong J, Chen M, Zheng Y, Wang S, Wang Y (2012) Polymeric micelles drug delivery system in oncology. J Control Release 159:312-323
71. Torchilin VP (2007) Micellar nanocarriers: pharmaceutical perspectives. Pharm Res 24(1):1-16. doi: 10.1007/s11095-006-9132-0
72. van Vlerken LE, Vyas TK, Amiji MM (2007) Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm Res 24(8):1405-1414. doi: 10.1007/s11095-007-9284-6
73. Chan JM, Zhang LF, Yuet KP, Liao G, Rhee JW, Langer R, Farokhzad OC (2009) PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials 30(8):1627-1634. doi: 10.1016/j.biomaterials.2008.12.013
74. Mansour HM, Sohn M, Al-Ghananeem A, DeLuca PP (2010) Materials for pharmaceutical dosage forms: molecular pharmaceutics and controlled release drug delivery aspects. Int J Mol Sci 11(9):3298-3322. doi: 10.3390/ijms11093298
75. Mohamed F, van der Walle CF (2008) Engineering biodegradable polyester particles with specific drug targeting and drug release properties. J Pharm Sci 97(1):71-87. doi: 10.1002/jps.21082
76. Yang L, Zhang LJ, Webster TJ (2011) Nanobiomaterials: state of the art and future trends. Adv Eng Mater 13(6):B197-B217. doi: 10.1002/adem.201080140
77. Bajpai AK, Shukla SK, Bhanu S, Kankane S (2008) Responsive polymers in controlled drug delivery. Prog Polym Sci 33(11):1088-1118. doi: 10.1016/j.progpolymsci.2008.07.005
78. Seyednejad H, Ghassemi AH, van Nostrum CF, Vermonden T, Hennink WE (2011) Functional aliphatic polyesters for biomedical and pharmaceutical applications. J Control Release 152(1):168-176. doi: 10.1016/j.jconrel.2010.12.016
79. Vroman I, Tighzert L (2009) Biodegradable polymers. Materials 2(2):307-344. doi: 10.3390/ma2020307
80. Park J, Mattessich T, Jay SM, Agawu A, Saltzman WM, Fahmy TM (2011) Enhancement of surface ligand display on PLGA nanoparticles with amphiphilic ligand conjugates. J Control Release 156(1):109-115
81. Gaucher GV, Marchessault RH, Leroux J-C (2010) Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes. J Control Release 143(1):2-12
82. Kumari A, Yadav SK, Yadav SC (2010) Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B-Biointerfaces 75(1):1-18. doi: 10.1016/j.colsurfb.2009.09.001
83. Liong M, Lu J, Kovochich M, Xia T, Ruehm SG, Nel AE, Tamanoi F, Zink JI (2008) Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. Acs Nano 2(5):889-896. doi: 10.1021/nn800072t
84. Park JH, Lee S, Kim JH, Park K, Kim K, Kwon IC (2008) Polymeric nanomedicine for cancer therapy. Prog Polym Sci 33(1):113-137. doi: 10.1016/j.progpolymsci.2007.09.003
85. Schroeder A, Heller DA, Winslow MM, Dahlman JE, Pratt GW, Langer R, Jacks T, Anderson DG (2012) Treating metastatic cancer with nanotechnology. Nat Rev Cancer 12(1):39-50
86. Zhou Q, Guo X, Chen T, Zhang Z, Shao SJ, Luo C, Li JR, Zhou SB (2011) Target-specific cellular uptake of folate-decorated biodegradable polymer micelles. J Phys Chem B 115(43):12662-12670. doi: 10.1021/jp207951e
87. Danquah MK, Zhang XA, Mahato RI (2011) Extravasation of polymeric nanomedicines across tumor vasculature. Adv Drug Deliv Rev 63(8):623-639
88. Jang SH, Wientjes MG, Lu D, Au JLS (2003) Drug delivery and transport to solid tumors. Pharm Res 20(9):1337-1350. doi: 10.1023/a:1025785505977
89. Liang CY, Yang YB, Ling Y, Huang YS, Li T, Li XM (2011) Improved therapeutic effect of folate-decorated PLGA-PEG nanoparticles for endometrial carcinoma. Bioorg Med Chem 19(13):4057-4066. doi: 10.1016/j.bmc.2011.05.016
90. Maeda H, Bharate GY, Daruwalla J (2009) Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm 71(3):409-419. doi: 10.1016/j.ejpb.2008.11.010
91. Maeda H, Greish K, Fang J (2006) The EPR effect and polymeric drugs: a paradigm shift for cancer chemotherapy in the 21st century. In: SatchiFainaro R, Duncan R (eds) Polymer therapeutics II: Polymers as drugs, conjugates and gene delivery systems. Adv Polym Sci 193:103-121. doi: 10.1007/12-026
92. Xu J, Ganesh S, Amiji M (2011) Non-condensing polymeric nanoparticles for targeted gene and siRNA delivery. Int J Pharm 427:21-34
93. Bae YH, Park K (2011) Targeted drug delivery to tumors: myths, reality and possibility. J Control Release 153(3):198-205
94. Couvreur P, Vauthier C (2006) Nanotechnology: intelligent design to treat complex disease. Pharm Res 23(7):1417-1450. doi: 10.1007/s11095-006-0284-8
95. Danhier F, Feron O, Preat V (2010) To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 148(2):135-146. doi: 10.1016/j.jconrel.2010.08.027
96. Lammers T, Kiessling F, Hennink WE, Storm G (2012) Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress. J Control Release 161:175-187
97. Lee ES, Gao ZG, Bae YH (2008) Recent progress in tumor pH targeting nanotechnology. J Control Release 132(3):164-170. doi: 10.1016/j.jconrel.2008. 05.003
98. Vladimir T (2009) Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur J Pharm Biopharm 71(3):431-444
99. Caldorera-Moore ME, Liechty WB, Peppas NA (2011) Responsive theranostic systems: integration of diagnostic imaging agents and responsive controlled release drug delivery carriers. Acc Chem Res 44(10):1061-1070. doi: 10.1021/ar2001777
100. Mahato R, Tai WY, Cheng K (2011) Prodrugs for improving tumor targetability and efficiency. Adv Drug Deliv Rev 63(8):659-670. doi: 10.1016/j.addr.2011.02.002
101. El-Aneed A (2004) An overview of current delivery systems in cancer gene therapy. J Control Release 94(1):1-14. doi: 10.1016/j.jconrel.2003.09.013
102. Guo P, Coban O, Snead NM, Trebley J, Hoeprich S, Guo S, Shu Y (2010) Engineering RNA for Targeted siRNA delivery and medical application. Adv Drug Deliv Rev 62(6):650-666
103. Hu C-MJ, Zhang L (2012) Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol 83(8):1104-1111
104. Patil Y, Panyam J (2009) Polymeric nanoparticles for siRNA delivery and gene silencing. Int J Pharm 367(1-2):195-203. doi: 10.1016/j.ijpharm.2008.09.039
105. Cheng J, Teply BA, Sherifi I, Sung J, Luther G, Gu FX, Levy-Nissenbaum E, Radovic-Moreno AF, Langer R, Farokhzad OC (2007) Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28(5):869-876. doi: 10.1016/j.biomaterials.2006.09.047
106. Kocbek P, Obermajer N, Cegnar M, Kos J, Kristl J (2007) Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J Control Release 120(1-2):18-26. doi: 10.1016/j.jconrel.2007.03.012
107. Liu Y, Li K, Pan J, Liu B, Feng S-S (2010) Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of Docetaxel. Biomaterials 31(2):330-338
108. Park J, Fong PM, Lu J, Russell KS, Booth CJ, Saltzman WM, Fahmy TM (2009) PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomed-Nanotechnol Biol Med 5(4):410-418. doi: 10.1016/j.nano.2009.02.002
109. Sutton D, Nasongkla N, Blanco E, Gao JM (2007) Functionalized micellar systems for cancer targeted drug delivery. Pharm Res 24(6):1029-1046. doi: 10.1007/s11095-006-9223-y
110. Zhou J, Patel TR, Fu M, Bertram JP, Saltzman WM (2012) Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors. Biomaterials 33(2):583-591
111. Efthimiadou EK, Tapeinos C, Bilalis P, Kordas G (2011) New approach in synthesis, characterization and release study of pH-sensitive polymeric micelles, based on PLA-Lys-b-PEGm, conjugated with doxorubicin. J Nanoparticle Res 13(12):6725-6736. doi: 10.1007/s11051-011-0579-5
112. Yoo J-W, Doshi N, Mitragotri S (2011) Adaptive micro and nanoparticles: temporal control over carrier properties to facilitate drug delivery. Adv Drug Deliv Rev 63(14-15):1247-1256
113. Rasal RM, Janorkar AV, Hirt DE (2010) Poly(lactic acid) modifications. Prog Polym Sci 35(3):338-356. doi: 10.1016/j.progpolymsci.2009.12.003
114. Thamake SI, Raut SL, Ranjan AP, Gryczynski Z, Vishwanatha JK (2011) Surface functionalization of PLGA nanoparticles by non-covalent insertion of a homo-bifunctional spacer for active targeting in cancer therapy. Nanotechnology 22(3):035101. doi: 10.1088/0957-4484/22/3/035101
115. Sussman EM, Clarke MB, Shastri VP (2007) Single-step process to produce surface-functionalized polymeric nanoparticles. Langmuir 23(24):12275-12279. doi: 10.1021/la701997x
116. Wiradharma N, Zhang Y, Venkataraman S, Hedrick JL, Yang YY (2009) Self-assembled polymer nanostructures for delivery of anticancer therapeutics. Nano Today 4(4):302-317. doi: 10.1016/j.nantod.2009.06.001
117. Chung YI, Kim JC, Kim YH, Tae G, Lee SY, Kim K, Kwon IC (2010) The effect of surface functionalization of PLGA nanoparticles by heparin- or chitosan-conjugated Pluronic on tumor targeting. J Control Release 143(3):374-382. doi: 10.1016/j.jconrel.2010.01.017
118. Parveen S, Sahoo SK (2011) Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery. Eur J Pharmacol 670(2-3):372-383
119. Bilensoy E, Sarisozen C, Esendagli G, Dogan AL, Aktas Y, Sen M, Mungan NA (2009) Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of Mitomycin C to bladder tumors. Int J Pharm 371(1-2):170-176. doi: 10.1016/j.ijpharm.2008.12.015
120. Chakravarthi SS, Robinson DH (2011) Enhanced cellular association of paclitaxel delivered in chitosan-PLGA particles. Int J Pharm 409(1-2):111-120. doi: 10.1016/j.ijpharm.2011.02.034
121. Khandare J, Minko T (2006) Polymer-drug conjugates: progress in polymeric prodrugs. Prog Polym Sci 31(4):359-397
122. Thanh NTK, Green LAW (2010) Functionalisation of nanoparticles for biomedical applications. Nano Today 5(3):213-230. doi: 10.1016/j.nantod.2010.05. 003
123. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ (2008) Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A 105(45):17356-17361. doi: 10.1073/pnas.0809154105
124. Zhao H, Yung LYL (2008) Selectivity of folate conjugated polymer micelles against different tumor cells. Int J Pharm 349(1-2):256-268
125. Pan J, Feng SS (2008) Targeted delivery of paclitaxel using folate-decorated poly(lactide) - vitamin E TPGS nanoparticles. Biomaterials 29(17):2663-2672. doi: 10.1016/j.biomaterials.2008.02.020
126. Wang C, Ho PC, Lim LY (2010) Wheat germ agglutinin-conjugated PLGA nanoparticles for enhanced intracellular delivery of paclitaxel to colon cancer cells. Int J Pharm 400(1-2):201-210
127. Heidel JD, Davis ME (2011) Clinical developments in nanotechnology for cancer therapy. Pharm Res 28(2):187-199. doi: 10.1007/s11095-010-0178-7
128. Lee SH, Mok H, Lee Y, Park TG (2011) Self-assembled siRNA-PLGA conjugate micelles for gene silencing. J Control Release 152(1):152-158. doi: 10.1016/j.jconrel.2010.12.007
129. Susa M, Milane L, Amiji MM, Hornicek FJ, Duan ZF (2011) Nanoparticles: a promising modality in the treatment of sarcomas. Pharm Res 28(2):260-272. doi: 10.1007/s11095-010-0173-z
130. Hans ML, Lowman AM (2002) Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci 6(4):319-327. doi: 10.1016/s1359-0286(02)00117-1
131. Xiong XB, Uludag H, Lavasanifar A (2009) Biodegradable amphiphilic poly(ethylene oxide)-block-polyesters with grafted polyamines as supramolecular nanocarriers for efficient siRNA delivery. Biomaterials 30(2):242-253. doi: 10.1016/j.biomaterials.2008.09.025
132. Bastani B, Fernandez D (2002) Intellectual property rights in nanotechnology. Thin Solid Films 420:472-477. doi: 10.1016/s0040-6090(02)00843-x
133. Merchant M (2010) Nanotechnology in Healthcare. Business Insights, 16-218
134. Koppikar V, Maebius S, Rutt S (2004) Current trends in nanotech patents: a view from inside the patent office. Nanotechnol Law Bus 1(1):24-30
135. Laurie A, Axford GRL (2006) Patent drafting considerations for nanotechnology inventions. Nanotechnol Law Bus 3(3):305
136. O'Neill S, Hermann K, Klein M, Landes J, Bawa R (2007) Broad claiming in nanotechnology patents: is litigation inevitable? Nanotechnol Law Bus 4(1):595-606
137. Fraser-Moodie I (2008) Delivery mechanisms for large molecule drugs. Business Insights, 10-138
138. EPO (2010) Guidelines for examination in the European Patent Office. Part C - guidelines for substantive examination - Chapter IV patentability.
139. Burgess P, Hutt PB, Farokhzad OC, Langer R, Minick S, Zale S (2010) On firm ground: IP protection of therapeutic nanoparticles. Nat Biotechnol 28(12):1267-1271. doi: 10.1038/nbt.1725
140. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335-2342. doi: 10.1056/NEJMoa032691
141. Shepherd FA, Pereira JR, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu DS, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L, Natl Canc Inst Canada Clin T (2005) Erlotinib in previously treated non-small-cell lung cancer. New Eng J Med 353(2):123-132. doi: 10.1056/NEJMoa050753
142. Kuesters GM, Campbell RB (2010) Conjugation of bevacizumab to cationic liposomes enhances their tumor-targeting potential. Nanomedicine 5(2):181-192. doi: 10.2217/nnm.09.105
143. Shorr R, Rodriguez R (2007) Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells. US patent no. 7,521,066
144. Borbely J, Bodnar M, Hartmann JF, Hajdu I, Kollar J, Vamosi G (2008) Cancer cell diagnosis by targeting delivery of nanodevices. US patent no. 7,976,825
145. Huff TB, Tong L, Zhao Y, Hansen MN, Cheng JX, Wei A (2007) Hyperthermic effects of gold nanorods on tumor cells. Nanomedicine 2(1):125-132. doi: 10.2217/17435889.2.1.125
146. Dixit V, Van den Bossche J, Sherman DM, Thompson DH, Andres RP (2006) Synthesis and grafting of thioctic acid-PEG-folate conjugates onto Au nanoparticles for selective targeting of folate receptor-positive tumor cells. Bioconjug Chem 17(3):603-609. doi: 10.1021/bc050335b
147. El-Sayed IH, Huang XH, El-Sayed MA (2006) Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles. Cancer Lett 239(1):129-135. doi: 10.1016/j.canlet.2005.07.035
148. Cleator S, Heller W, Coombes RC (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8(3):235-244. doi: 10.1016/s1470-2045(07) 70074-8
149. Oyelere Adegboyega K, EL-Sayed Mostafa A, Dreaden EC (2009) Targeted cellular delivery of nanoparticles. US Patent application no. 2011077581
150. Akhtari M, Engel J (2009) Use of functionalized magnetic nanoparticles in cancer detection and treatment. US Patent application no. 2011044911
151. Layton B (2008) Recent patents in bionanotechnologies: nanolithography, bionanocomposites, cell-based computing and entropy production. US patent no. 7,638,558
152. Liu L, Li C, Li X, Yuan Z, An Y, He B (2001) Biodegradable polylactide/poly(ethylene glycol)/polylactide triblock copolymer micelles as anticancer drug carriers. J Appl Polym Sci 80(11):1976-1982. doi: 10.1002/app.1295
153. Radosz M, Xu P, Shen Y (2005) Nanoparticles for cytoplasmic drug delivery to cancer cells. US Patent application no. 2010203149
154. Desai NP, Soon-Shiong P (2007) Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane. US Patent application no. 20070519126
155. Moradi M (2005) Global developments in nano-enabled drug delivery market. Nanothecnology Law & Business 2(2):139-148